ASCO Annual Meeting: Lung Cancer

Experts recap of the most pivotal lung cancer data to surface at the 2026 ASCO Annual Meeting.

First-line asandeutertinib improved intracranial iORR and IPFS vs osimertinib in EGFR-mutated NSCLC with brain metastases.

FLAME data show ctDNA-guided addition of chemotherapy to osimertinib improved PFS vs osimertinib alone in EGFR-mutant NSCLC.

The phase 3 HARMONi-6 showed an overall survival benefit with ivonescimab plus chemotherapy vs tislelizumab plus chemotherapy in squamous NSCLC.

Adjuvant selpercatinib cut recurrence or death risk by 83% vs placebo in stage IB-IIIA RET fusion–positive NSCLC in LIBRETTO-432.

Seven-year follow-up from the CROWN trial has set a tall benchmark for the agents that followed it on the podium at the 2026 ASCO Annual Meeting in oncogene driven NSCLC.

The phase 3 WU-KONG28 data showed that first-line sunvozertinib improved PFS and ORR vs chemotherapy in EGFR exon 20–mutant NSCLC.

The combination cut the risk of progression or death by 65% in the first phase 3 trial of an ADC plus pembrolizumab in this setting.

Amivantamab plus lazertinib led to a median OS of 41.0 months in EGFR-mutated advanced NSCLC.

RET rechallenge following disease progression demonstrated greater efficacy with select combination therapies targeting bypass resistance vs single agents.

THIO plus cemiplimab showed tolerability and activity in ICI-resistant advanced NSCLC in the second- and third-line settings.

Frontline BNT327/PM8002 plus chemotherapy was effective and safe in patients with unresectable pleural and peritoneal mesothelioma.

Benmelstobart with or without anlotinib boosted progression-free survival after chemoradiotherapy in unresectable stage III non–small cell lung cancer.

Neoadjuvant nivolumab plus chemo significantly improved OS vs chemo alone in resectable NSCLC, supporting practice-changing potential.

Tarlatamab improved overall survival and progression-free survival in the second-line treatment of small cell lung cancer.

Neoadjuvant osimertinib as monotherapy or plus chemotherapy was more effective vs chemotherapy alone in patients with resectable EGFR-mutated NSCLC.

COCOON DM reduced the severity and QOL influence of dermatologic AEs vs SOC DM in EGFR-mutant, advanced NSCLC treated with amivantamab plus lazertinib.

Neoadjuvant chemotherapy and nivolumab and adjuvant nivolumab prolonged EFS vs placebo in patients with resectable NSCLC in follow-up from CheckMate-77T.

The DLL3-directed CAR T-cell therapy LB2102 was safe with preliminary antitumor activity in small cell lung cancer and large cell neuroendocrine carcinoma.

Neoadjuvant alectinib produced major pathologic responses, and it was tolerable and feasible in potentially resectable, stage III, ALK-positive NSCLC.

Adding induction toripalimab to chemotherapy followed by definitive chemoradiotherapy and consolidation therapy reduced risk for disease progression by 74%.